Pfizer Inc. (NYSE:PFE) Given Average Rating of “Hold” by Brokerages

Pfizer Inc. (NYSE:PFE) has earned a consensus rating of “Hold” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $35.86.

PFE has been the subject of several research reports. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, June 17th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC raised its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the fourth quarter valued at about $36,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.0 %

Shares of Pfizer stock opened at $27.75 on Monday. The company’s fifty day simple moving average is $27.67 and its 200-day simple moving average is $27.72. The company has a market cap of $157.22 billion, a price-to-earnings ratio of -462.34, a PEG ratio of 1.08 and a beta of 0.70. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer has a 1 year low of $25.20 and a 1 year high of $38.99.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.23 earnings per share. As a group, sell-side analysts expect that Pfizer will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were issued a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.06%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.